The human mtDNA is a compact circular genome (16.6 kb) coding for components of the ATP-producing oxidative phosphorylation system. The contribution of the mitochondrial genome to cellular respiration, though vital, is not sufficient. Dozens of nuclear DNA (nDNA) coded proteins synthesized in the cytoplasm are imported into mitochondria and assembled with mitochondrially-synthesized proteins to form a functional oxidative phosphorylation system.
Mutations of either mtDNA or nDNA have been associated with devastating clinical syndromes. Organs with high energy requirements such as brain and muscle are preferentially affected. Symptoms include: seizures, strokes, muscle weakness, blindness, diabetes, and hearing loss. In addition to defining novel mtDNA abnormalities in patients with mitochondrial disorders, we are interested in understanding the molecular pathogenesis of these mutations and developing novel approaches to therapy. We use a full array of molecular and cell biology techniques for these studies.
Currently we have four major funded projects:
1) Development of genetic therapies for mitochondrial diseases. We are focusing on altering the ratio of mutant/wild-type mtDNA by the use of mitochondria-targeted endonucleases.
2) Development of animal models to study the pathogenesis of mitochondrial disorders. We are studying the molecular pathogenesis of several mitochondrial disorders with the help of genetically engineered mouse models.
3) The role of cytochrome c in apoptosis and development. WE have developed genetically modified mice with a defect in cytochrome c in various tissues. We are using this model to study the role of cytochrome c in apoptosis.
4) Compensating for a defect in oxidative phosphorylation by increasing mitochondrial biogenesis. We have found that the transcription coactivator PGC-1alpha, a major regulator of mitochondrial biogenesis, can compensate for partial mitochondrial defects when overexpressed.
|

|
|
A recombinant mitochondria-targeted restriction endonuclease was expressed in mouse skeletal muscle with the use of an adenovirus vector. The restriction endonuclease localized to muscle mitochondria (green). Because the restriction enzyme used (ApaLI) could digest a specific type of mtDNA sequence, subsequent analysis of the ratio "mutant"/wild-type mtDNA showed a marked reduction in the "mutant." |
|